Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 14/20 | 0.62 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.62 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.53 |
| ▸ | NAMPT | P43490 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1027671 | 0.95 | HDAC6 (0.56) | HDAC6HDAC8HDAC1HDAC3NAMPT | |
| SCHEMBL1029161 | 0.80 | HDAC6 (0.59) | HDAC6HDAC8HDAC1HDAC3 | |
| SCHEMBL1028114 | 0.80 | MAPT (0.61) | HDAC6HDAC8HDAC1HDAC3 | |
| SCHEMBL2279957 | 0.79 | NAMPT (0.44) | HDAC6HDAC8NAMPTKDM4E | |
| SCHEMBL1264127 | 0.79 | HDAC6 (0.64) | HDAC6HDAC8HDAC1HDAC3KDM1A | |
| SCHEMBL2277596 | 0.79 | HDAC6 (0.58) | HDAC6HDAC8HDAC1HDAC3NAMPT | |
| SCHEMBL1027560 | 0.78 | HDAC6 (0.73) | HDAC6HDAC8HDAC1HDAC3 | |
| SCHEMBL1263305 | 0.77 | HDAC6 (1.00) | HDAC6HDAC8HDAC1HDAC3 | |
| SCHEMBL1264708 | 0.76 | HDAC6 (0.63) | HDAC6HDAC8HDAC1HDAC3KDM1A | |
| SCHEMBL2281130 | 0.76 | HDAC6 (0.60) | HDAC6HDAC8HDAC1HDAC3KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575193-B2 | N-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds | 4SC AG (DE) | 2013-11-05 | — | — | US | claimed |
| US-20110201643-A1 | NOVEL N-SUBSTITUTED TETRAHYDROISOQUINOLINE/ISOINDOLINE HYDROXAMIC ACID COMPOUNDS | 4SC AG (DE) | 2011-08-18 | — | — | US | claimed |
| EP-2274283-A1 | NOVEL N-SUBSTITUTED TETRAHYDROISOQUINOLINE/ISOINDOLINE HYDROXAMIC ACID COMPOUNDS | 4SC AG (DE) | 2011-01-19 | — | — | EP | claimed |
| WO-2009112550-A1 | NOVEL N-SUBSTITUTED TETRAHYDROISOQUINOLINE/ISOINDOLINE HYDROXAMIC ACID COMPOUNDS | 4SC AG (DE) | 2009-09-17 | — | — | WO | claimed |
| EP-2100879-A1 | Novel N-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds | 4SC AG (DE) | 2009-09-16 | — | — | EP | claimed |
| US-8575193-B2 | N-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds | 4SC AG (DE) | 2013-11-05 | — | — | US | disclosed |
| US-20110201643-A1 | NOVEL N-SUBSTITUTED TETRAHYDROISOQUINOLINE/ISOINDOLINE HYDROXAMIC ACID COMPOUNDS | 4SC AG (DE) | 2011-08-18 | — | — | US | disclosed |
| EP-2274283-A1 | NOVEL N-SUBSTITUTED TETRAHYDROISOQUINOLINE/ISOINDOLINE HYDROXAMIC ACID COMPOUNDS | 4SC AG (DE) | 2011-01-19 | — | — | EP | disclosed |
| WO-2009112550-A1 | NOVEL N-SUBSTITUTED TETRAHYDROISOQUINOLINE/ISOINDOLINE HYDROXAMIC ACID COMPOUNDS | 4SC AG (DE) | 2009-09-17 | — | — | WO | disclosed |
| EP-2100879-A1 | Novel N-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds | 4SC AG (DE) | 2009-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201643-A1 | NOVEL N-SUBSTITUTED TETRAHYDROISOQUINOLINE/ISOINDOLINE HYDROXAMIC ACID COMPOUNDS | HDAC1, HDAC3, HDAC4 | HDAC6 7/4885HDAC8 10/4885HDAC1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.